Repository logo
 

Biological basis for novel mesothelioma therapies

Published version
Peer-reviewed

Change log

Authors

Yung, Henry 
Shamseddin, Marie 
Linnane, Emily 
Liu, Xiewen 

Abstract

Abstract: Mesothelioma is an aggressive cancer that is associated with exposure to asbestos. Although asbestos is banned in several countries, including the UK, an epidemic of mesothelioma is predicted to affect middle-income countries during this century owing to their heavy consumption of asbestos. The prognosis for patients with mesothelioma is poor, reflecting a failure of conventional chemotherapy that has ultimately resulted from an inadequate understanding of its biology. However, recent work has revolutionised the study of mesothelioma, identifying genetic and pathophysiological vulnerabilities, including the loss of tumour suppressors, epigenetic dysregulation and susceptibility to nutrient stress. We discuss how this knowledge, combined with advances in immunotherapy, is enabling the development of novel targeted therapies.

Description

Funder: British Lung Foundation (BLF); doi: https://doi.org/10.13039/501100000351


Funder: Royal Society through a University Research Fellowship and the Engineering and Physical Sciences Research Council (EPRSC)


Funder: China Scholarship Council (CSC); doi: https://doi.org/10.13039/501100004543

Keywords

Review Article, /631/67/1641, /631/80/304, review-article

Journal Title

British Journal of Cancer

Conference Name

Journal ISSN

0007-0920
1532-1827

Volume Title

125

Publisher

Nature Publishing Group UK